Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo pill aims to boost Insulin's power against diabetes

NCT ID NCT02220920

First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 23 times

Summary

This study tested whether adding canagliflozin, a diabetes pill, to insulin therapy helps people with type 2 diabetes control their blood sugar better. 146 adults who were already on a stable insulin dose took either canagliflozin or a placebo for 16 weeks. Researchers measured changes in blood sugar levels, weight, and blood pressure, and monitored for side effects like low blood sugar.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Reserch site

    Chugoku, Japan

  • Reserch site

    Chūbu, Japan

  • Reserch site

    Hokkaido, Japan

  • Reserch site

    Kanto, Japan

  • Reserch site

    Kinki, Japan

  • Reserch site

    Kyushu, Japan

  • Reserch site

    Tōhoku, Japan

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Canagliflozin

What this could lead to

If it works, this could provide an additional treatment option for people with type 2 diabetes who need better blood sugar control despite using insulin.

What could go wrong

This is a completed Phase 4 trial with only 146 participants, so results may not apply to everyone. Canagliflozin can increase the risk of hypoglycemia (low blood sugar) when combined with insulin.

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.